Base de dados : MEDLINE
Pesquisa : D06.472.699.631.525.425.875 [Categoria DeCS]
Referências encontradas : 12018 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1202 ir para página                         

  1 / 12018 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465564
[Au] Autor:Wójcik D; Krzewska A; Szalewski L; Pietryka-Michalowska E; Szalewska M; Krzewski S; Pels E; Ben-Skowronek I
[Ad] Endereço:Chair and Department of Paedodontics, Medical University of Lublin, Poland.
[Ti] Título:Dental caries and vitamin D3 in children with growth hormone deficiency: A STROBE compliant study.
[So] Source:Medicine (Baltimore);97(8):e9811, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vitamin D may prevent dental caries. To date, no attempts have been made to examine the correlation between the incidence of caries and the concentrations of vitamin D in children with pituitary growth hormone deficiency.The study observed patients of the Department of Endocrinology and Diabetology of the University Paediatric Hospital of the Medical University of Lublin treated with human recombinant growth hormone for pituitary growth hormone deficiency (GHD). The study was conducted between October 2014 and June 2015. The study group consisted of 121 children and adolescents (6-17 years old), including 56 children from rural areas and 65 children from urban areas. The study group was stratified by area of residence.In our study, the increase in vitamin D3 [25(OH)D] levels reduced the D component by 0.66 per each 10 ng/mL of vitamin D3 concentration. The percentage of children with active caries in rural areas is 91.07% (n = 51), which is significantly higher than the percentage of children with active caries in urban areas (81.54%, n = 53).To date, information regarding the potential possibility of reducing the incidence of dental caries by means of increasing the levels of vitamin D was sidelined by paediatricians and dentists alike. Therefore, this aspect of caries prevention should be highlighted.
[Mh] Termos MeSH primário: Colecalciferol/sangue
Cárie Dentária/sangue
Cárie Dentária/epidemiologia
Hormônio do Crescimento Humano/deficiência
[Mh] Termos MeSH secundário: Adolescente
Criança
Colecalciferol/uso terapêutico
Índice CPO
Cárie Dentária/prevenção & controle
Hormônio do Crescimento Humano/uso terapêutico
Seres Humanos
Incidência
Higiene Bucal
Polônia/epidemiologia
População Rural/estatística & dados numéricos
População Urbana/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
12629-01-5 (Human Growth Hormone); 1C6V77QF41 (Cholecalciferol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009811


  2 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351335
[Au] Autor:Berry NT; Hubal M; Wideman L
[Ad] Endereço:University of North Carolina at Greensboro, Greensboro, NC, United States of America.
[Ti] Título:The effects of an acute exercise bout on GH and IGF-1 in prediabetic and healthy African Americans: A pilot study investigating gene expression.
[So] Source:PLoS One;13(1):e0191331, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The incidence of pre-diabetes (PD) and Type-2 Diabetes Mellitus (T2D) is a worldwide epidemic. African American (AA) individuals are disproportionately more likely to become diabetic than other ethnic groups. Over the long-term, metabolic complications related to diabetes result in significant alterations in growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Considering the limited exercise-related studies in the area of gene expression changes with disease progression, the objective of this study was to examine differences in exercise-induced gene expression related to the GH and IGF-1 pathways in peripheral blood mononuclear cells (PBMCs) of healthy (CON) and PD AA individuals. DESIGN: Ten subjects [5 PD (age = 35±9.3 yr, BMI = 32.1±4.0, FBG = 101.8±1.3 mg/dl) and 5 CON (age = 31±9.4 yr, BMI = 29.4±5.2, FBG = 82.8±9.7 mg/dl)] had blood drawn for RNA isolation prior to exercise (Pre), immediately following acute moderate intensity exercise on a treadmill (Post-1), 6-hours post (Post-6), and 24-hours post (Post-24). Isolation of mRNA from PBMCs was performed using ficoll separation, while the profiling of mRNA expression was performed using Illumina beadchip arrays with standard protocols. Scan results were statistically analyzed for a specific list of genes related to GH and IGF-1. GH and IGF-1 protein levels were also assessed in each sample. To address issues of normality, all GH and IGF-1 data were log-transformed prior to analysis. Statistical significance was set at p<0.05. RESULTS: Group differences for GH2 variant 2 (p = 0.070) and GH2 variant 3 (p = 0.059) were coupled with significant alterations in IGF-1 mRNA over time (p = 0.024). A significant interaction between group and time was observed for GHRH mRNA (p = 0.008). No group differences were observed in GH AUC (p = 0.649), ΔGH (p = 0.331), GHrec (p = 0.294), or IGF-1 AUC (p = 0.865), representing a similar exercise-induced GH and IGF-1 response for both groups. CONCLUSIONS: Analysis of GH and IGF-1 related-gene expression indicates that mild elevations in fasting blood glucose and exercise-induced alterations in gene expression are impacted by the prediabetic state.
[Mh] Termos MeSH primário: Afroamericanos/genética
Regulação da Expressão Gênica
Hormônio do Crescimento Humano/genética
Fator de Crescimento Insulin-Like I/genética
Estado Pré-Diabético/genética
[Mh] Termos MeSH secundário: Adulto
Glicemia/metabolismo
Estudos de Casos e Controles
Jejum/sangue
Feminino
Hormônio do Crescimento Humano/metabolismo
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Masculino
Projetos Piloto
Estado Pré-Diabético/sangue
Estado Pré-Diabético/metabolismo
Estado Pré-Diabético/fisiopatologia
Transporte Proteico
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Blood Glucose); 0 (RNA, Messenger); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191331


  3 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223399
[Au] Autor:Kim H; Kim H; Kim K; German MS; Kim H
[Ad] Endereço:Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea.
[Ti] Título:Ectopic serotonin production in ß-cell specific transgenic mice.
[So] Source:Biochem Biophys Res Commun;495(2):1986-1991, 2018 01 08.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Genetically modified mice have been widely used in the field of ß-cell research. However, analysis of results gathered using genetically modified organisms should be interpreted carefully as the results may be confounded by several factors. Here, we showed the ectopic serotonin (5-HT) production in ß-cells of RIP-Cre , MIP-GFP, and MIP-Cre/ERT mice. These mice contained a human growth hormone (hGH) cassette to enhance transgene expression and hGH expression and Stat5 phosphorylation were detected in pancreatic islets of these mice. The expression level of tryptophan hydroxylase 1 (Tph1) was upregulated in pancreatic islets of transgenic mice with an hGH cassette but not in transgenic mice without an hGH cassette. Ectopic 5-HT production was not observed in ß-cell-specific prolactin receptor (Prlr) knockout mice or Stat5 knockout mice crossed with RIP-Cre . We further confirmed that 5-HT production in ß-cells of several transgenic mice was induced by hGH expression followed by the activation of the Prlr-Stat5-Tph1 pathway. These findings indicate that results obtained using transgenic mice containing the hGH cassette should be interpreted with care.
[Mh] Termos MeSH primário: Linfócitos B/secreção
Hormônio do Crescimento Humano/genética
Hormônio do Crescimento Humano/metabolismo
Camundongos Transgênicos/genética
Camundongos Transgênicos/metabolismo
Serotonina/genética
Serotonina/secreção
[Mh] Termos MeSH secundário: Animais
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
12629-01-5 (Human Growth Hormone); 333DO1RDJY (Serotonin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  4 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328563
[Au] Autor:Dragovic T; Duran Z; Jelic S; Marinkovic D; Kikovic S; Kuzmic-Jankovic S; Hajdukovic Z
[Ti] Título:Coexisting diseases modifying each other's presentation - lack of growth failure in Turner syndrome due to the associated pituitary gigantism.
[So] Source:Vojnosanit Pregl;73(10):961-6, 2016 Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Turner syndrome presents with one of the most frequent chromosomal aberrations in female, typically presented with growth retardation, ovarian insufficiency, facial dysmorphism, and numerous other somatic stigmata. Gigantism is an extremely rare condition resulting from an excessive growth hormone (GH) secretion that occurs during childhood before the fusion of epiphyseal growth plates. The major clinical feature of gigantism is growth acceleration, although these patients also suffer from hypogonadism and soft tissue hypertrophy. Case report: We presented a girl with mosaic Turner syndrome, delayed puberty and normal linear growth for the sex and age, due to the simultaneous GH hypersecretion by pituitary tumor. In the presented case all the typical phenotypic stigmata related to Turner syndrome were missing. Due to excessive pituitary GH secretion during the period while the epiphyseal growth plates of the long bones are still open, characteristic stagnation in longitudinal growth has not been demonstrated. The patient presented with delayed puberty and primary amenorrhea along with a sudden appearance of clinical signs of hypersomatotropinism, which were the reasons for seeking medical help at the age of 16. Conclusion: Physical examination of children presenting with delayed puberty but without growth arrest must include an overall hormonal and genetic testing even in the cases when typical clinical presentations of genetic disorder are absent. To the best of our knowledge, this is the first reported case of simultaneous presence of Turner syndrome and gigantism in the literature.
[Mh] Termos MeSH primário: Adenoma/complicações
Desenvolvimento do Adolescente
Estatura
Gigantismo/etiologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/complicações
Síndrome de Turner/complicações
[Mh] Termos MeSH secundário: Adenoma/sangue
Adenoma/fisiopatologia
Adenoma/cirurgia
Adolescente
Amenorreia/etiologia
Amenorreia/fisiopatologia
Biomarcadores/sangue
Feminino
Gigantismo/sangue
Gigantismo/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Terapia de Reposição Hormonal
Hormônio do Crescimento Humano/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Imagem por Ressonância Magnética
Mosaicismo
Puberdade Tardia/etiologia
Puberdade Tardia/fisiopatologia
Resultado do Tratamento
Síndrome de Turner/tratamento farmacológico
Síndrome de Turner/genética
Síndrome de Turner/fisiopatologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (IGF1 protein, human); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150620014D


  5 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29172979
[Au] Autor:Sagi S; Cohen HP; Woollett GR
[Ad] Endereço:1 Sandoz Biopharmaceuticals, Singapore.
[Ti] Título:Pharmacovigilance of Biologics in a Multisource Environment.
[So] Source:J Manag Care Spec Pharm;23(12):1249-1254, 2017 Dec.
[Is] ISSN:2376-1032
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:It is important that systems are in place to ensure that appropriate and comprehensive records are kept for use of all medications. It is fundamental to an effective pharmacovigilance system that patient medical records contain sufficient information to identify which medication has been prescribed, when it was administered, and at what dose. The availability of biologics from multiple sponsors has raised questions by some health care providers about the ability of current pharmacovigilance systems to trace specific biologics. In this article, periodic safety update reports were used to assess current postapproval safety monitoring for 3 biosimilars (epoetin alfa, somatropin, and filgrastim) that collectively represented nearly 350 million patient days of treatment worldwide. The reference products have each been marketed for over 10 years, forming a strong baseline of postmarketing safety data against which the safety of biosimilars can be compared. Published data from Denmark were also reviewed as additional evidence of how current pharmacovigilance systems are able to attribute adverse events to particular medicines. Collectively, the data show that spontaneous adverse drug reactions are reported by brand name in the majority of cases and are attributable to a specific medicine. Also discussed are the informational elements critical to monitoring biologics, or indeed any medicine, to ensure the availability of complete information so medicines that a patient has received can be quickly identified should a safety event occur. We support the addition of a single data element, the batch/lot number, to enhance the value of current pharmacovigilance systems. Adoption of 2-D barcodes in the European Union (EU) and standardized numerical identifiers in the United States addresses this need, since they include batch/lot numbers. These identifiers are already being implemented in the United States and the EU to improve patient safety, reduce medication errors, facilitate anticounterfeiting, and enable effective product recalls and adverse event reporting. Importantly, electronic identifiers will ameliorate safety reporting concerns with respect to biosimilars, while concurrently achieving these much broader public health objectives through more complete pharmacovigilance data. DISCLOSURES: This work was funded by Sandoz, a Novartis division. The authors were fully responsible for the content, editorial decisions, and opinions expressed in this article. No author received an honorarium related to the development of this manuscript. Sagi and Cohen are employees of Sandoz, and Woollett is an employee of Avalere Health. Study concept and design were contributed by Sagi and Woollett, along with Cohen. Data were primarily collected by Sagi, along with Woollett, and data interpretation was provided by all the authors. The manuscript was written by Woollett, along with Sagi and Cohen, and revised by Sagi and Cohen, along with Woollett.
[Mh] Termos MeSH primário: Medicamentos Biossimilares/efeitos adversos
Epoetina alfa/efeitos adversos
Filgrastim/efeitos adversos
Hormônio do Crescimento Humano/efeitos adversos
Farmacovigilância
[Mh] Termos MeSH secundário: Sistemas de Notificação de Reações Adversas a Medicamentos
Processamento Automatizado de Dados/métodos
Produtos Biológicos/administração & dosagem
Produtos Biológicos/efeitos adversos
Medicamentos Biossimilares/administração & dosagem
Medicamentos Falsificados
Epoetina alfa/administração & dosagem
União Europeia
Filgrastim/administração & dosagem
Hormônio do Crescimento Humano/administração & dosagem
Seres Humanos
Erros de Medicação/prevenção & controle
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Biosimilar Pharmaceuticals); 0 (Counterfeit Drugs); 12629-01-5 (Human Growth Hormone); 64FS3BFH5W (Epoetin Alfa); PVI5M0M1GW (Filgrastim)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.18553/jmcp.2017.23.12.1249


  6 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467344
[Au] Autor:Soliman AT; De Sanctis V; Yassin M; Adel A
[Ad] Endereço:Department of Pediatrics, Alexandria University Children Hospital, Elchatby, Alexandria, Egypt. vdesanctis@libero.it.
[Ti] Título:Growth and Growth hormone - Insulin Like Growth Factor -I (GH-IGF-I) Axis in Chronic Anemias.
[So] Source:Acta Biomed;88(1):101-111, 2017 Apr 28.
[Is] ISSN:0392-4203
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Anaemia is a global public health problem affecting both developing and developed countries with major consequences for human health as well as social and economic development. It occurs at all stages of the life cycle, but is more prevalent in pregnant women and young children. Iron deficiency anaemia (IDA) was considered to be among the most important contributing factors to the global burden of disease. Prolonged and/or chronic anemia has a negative effect on linear growth especially during the rapid phases (infancy and puberty). Additionally infants with chronic IDA have delayed cognitive, motor, and affective development that may be long-lasting. In view of the significant impact of chronic anemias on growth, pediatricians endocrinologists and hematologists should advocate primary prevention and screening for growth disturbance in these forms of anemias. The extent of the negative effect of different forms of chronic anemias on linear growth and its possible reversibilty is addressed in this review. The possible mechanisms that may impair growth in the different forms of anemias are addressed with special attention to their effect on the growth hormone (GH) - insulin like growth factor -I (IGF-I).
[Mh] Termos MeSH primário: Anemia Ferropriva/sangue
Anemia Ferropriva/terapia
Desenvolvimento Infantil
Hormônio do Crescimento Humano/sangue
Fator de Crescimento Insulin-Like I/análise
[Mh] Termos MeSH secundário: Anemia Falciforme/complicações
Animais
Suplementos Nutricionais
Feminino
Seres Humanos
Lactente
Recém-Nascido de Baixo Peso
Ferro/uso terapêutico
Gravidez
Complicações Hematológicas na Gravidez
Talassemia/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I); E1UOL152H7 (Iron)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.23750/abm.v88i1.5744


  7 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28740584
[Au] Autor:Sharma MD; Nguyen AV; Brown S; Robbins RJ
[Ad] Endereço:Houston Methodist Hospital, Houston, Texas.
[Ti] Título:Cardiovascular Disease in Acromegaly.
[So] Source:Methodist Debakey Cardiovasc J;13(2):64-67, 2017 Apr-Jun.
[Is] ISSN:1947-6108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In patients with acromegaly, chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) leads to the development of acromegalic cardiomyopathy. Its main features are biventricular hypertrophy, diastolic dysfunction, and in later stages, systolic dysfunction and congestive heart failure. Surgical and/or pharmacological treatment of acromegaly and control of cardiovascular risk factors help reverse some of these pathophysiologic changes and decrease the high risk of cardiovascular complications.
[Mh] Termos MeSH primário: Acromegalia/fisiopatologia
Doenças Cardiovasculares/fisiopatologia
Sistema Cardiovascular/fisiopatologia
[Mh] Termos MeSH secundário: Acromegalia/sangue
Acromegalia/diagnóstico
Acromegalia/epidemiologia
Doenças Cardiovasculares/sangue
Doenças Cardiovasculares/diagnóstico
Doenças Cardiovasculares/epidemiologia
Sistema Cardiovascular/metabolismo
Hormônio do Crescimento Humano/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Prognóstico
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (IGF1 protein, human); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.14797/mdcj-13-2-64


  8 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29217803
[Au] Autor:Vyas V; Kumar A; Jain V
[Ad] Endereço:Department of Pediatrics,AIIMS, Jodhpur; and #Division of Pediatric Endocrinology, Department of Pediatrics, AIIMS, New Delhi; India. Correspondence to: Dr Vandana Jain, Professor, Division of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, NewDelhi 110029. drvandanajain@gmail.com.
[Ti] Título:Growth Hormone Deficiency in Children: From Suspecting to Diagnosing.
[So] Source:Indian Pediatr;54(11):955-960, 2017 Nov 15.
[Is] ISSN:0974-7559
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Isolated Growth hormone deficiency is an important and treatable cause of short stature. However, it is often difficult to diagnose the condition with certainty due to the lack of a single robust diagnostic test. Short children, other than those with the classical phenotype of immature chubby facies, truncal obesity and micropenis in boys, or those with history of cranial lesions with known association with hypopituitarism, should be evaluated for growth hormone deficiency only after excluding the other more common conditions. These children typically have height markedly below that expected for their midparental height with low height velocity and delayed bone age. Growth hormone levels should be checked by provocative testing, after ensuring that the child is euthyroid, and after priming with sex steroids if indicated. Low levels of Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 and pituitary abnormalities on neuroimaging provide important corroborative evidence to the diagnosis.
[Mh] Termos MeSH primário: Transtornos do Crescimento
Hormônio do Crescimento Humano/deficiência
Hipopituitarismo
[Mh] Termos MeSH secundário: Estatura/fisiologia
Criança
Feminino
Transtornos do Crescimento/diagnóstico
Transtornos do Crescimento/etiologia
Transtornos do Crescimento/fisiopatologia
Seres Humanos
Hipopituitarismo/diagnóstico
Hipopituitarismo/etiologia
Hipopituitarismo/fisiopatologia
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
12629-01-5 (Human Growth Hormone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  9 / 12018 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29192748
[Au] Autor:Hernán Martínez J; Mangual Garcia MM; Gutiérrez Acevedo M; Sánchez Cruz A; Laboy I; Rivera C; Mansilla P; Palermo Garofalo C; Lourdes Miranda M; Torres Rafael O
[Ti] Título:A middle aged woman with isolated ACTH deficiency associated with transient growth hormone deficiency.
[So] Source:Bol Asoc Med P R;108(1):3-6, 2016.
[Is] ISSN:0004-4849
[Cp] País de publicação:Puerto Rico
[La] Idioma:eng
[Ab] Resumo:Isolated ACTH deficiency (IAD) is a rare entity characterized by secondary adrenal insufficiency with low levels of serum cortisol, decreased production of ACTH, adequate secretion of other pituitary hormones and normal pituitary structure on radioimaging. The prevalence of IAD as a cause of secondary adrenal insufficiency has not been determined. Impairment of growth hormone (GH) secretion has been noted in 20 to 30% of patients with IAD which is normalized after glucocorticoid replacement. We report the case of a 50 years-old female with symptoms and laboratory results suggestive of adrenal insufficiency. Insulin tolerance test confirmed ACTH and growth hormone deficiency. The rest of the anterior pituitary hormones were normal. A pituitary MRI was unremarkable. Glucocorticoid replacement therapy started and eight months afterwards glucagon stimulation test revealed persistent ACTH deficiency but nor- mal growth hormone secretion. IAD can present with nonspecific symptoms and could be potentially fatal in an acute stressful period. Prompt recognition is essential to decrease morbidity and mortality.
[Mh] Termos MeSH primário: Hormônio Adrenocorticotrópico/deficiência
Doenças do Sistema Endócrino/complicações
Doenças Genéticas Inatas/complicações
Glucocorticoides/administração & dosagem
Hormônio do Crescimento Humano/deficiência
Hipoglicemia/complicações
Resistência à Insulina
[Mh] Termos MeSH secundário: Doenças do Sistema Endócrino/diagnóstico
Feminino
Doenças Genéticas Inatas/diagnóstico
Terapia de Reposição Hormonal/métodos
Seres Humanos
Hipoglicemia/diagnóstico
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 12629-01-5 (Human Growth Hormone); 9002-60-2 (Adrenocorticotropic Hormone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  10 / 12018 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28993415
[Au] Autor:Dal J; Klose M; Heck A; Andersen M; Kistorp C; Nielsen EH; Bollerslev J; Feldt-Rasmussen U; Jørgensen JOL
[Ad] Endereço:Department of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus, Denmark.
[Ti] Título:Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study.
[So] Source:Eur J Endocrinol;178(1):67-76, 2018 Jan.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Discordant GH and IGF-I values are frequent in acromegaly. The clinical significance and its dependence on treatment modality and of glucose-suppressed GH (GH ) measurements remain uncertain. OBJECTIVE: To evaluate the effects of targeting IGF-I GH during somatostatin analogue (SA) treatment. PATIENTS AND METHODS: 84 patients with controlled acromegaly after surgery ( = 23) or SA ( = 61) underwent a GH profile including an OGTT, at baseline and after 12 months. SA patients were randomized to monitoring according to either IGF-I ( = 33) or GH ( = 28). SA dose escalation was allowed at baseline and 6 months. MAIN OUTCOME MEASURES: GH and IGF-I at baseline and 12 months, and disease-specific Quality of Life (QoL). RESULTS: IGF-I and fasting GH levels were comparable between the surgery and the SA group, whereas GH (µg/L) was lower in the surgery group (GH 0.7 ± 0.1 vs 0.3 ± 0.1, < 0.01). SA dose increase was performed in 20 patients in the GH group and in 8 patients in the IGF-I group ( = 0.02), which increased the number of concordantly controlled patients ( = 0.01). QoL was only mildly affected at baseline in all groups and did not changed consistently during the study. CONCLUSION: (1) Discordant values in terms of high GH levels are prevalent in SA patients and more so if applying glucose-suppressed GH ; (2) targeting discordant levels of either GH or IGF-I translates into SA dose increase and improved biochemical control; (3) even though QoL was not improved in this study, we suggest biochemical assessment of disease activity to include glucose-suppressed GH also in SA patients.
[Mh] Termos MeSH primário: Acromegalia/sangue
Acromegalia/tratamento farmacológico
Sistemas de Liberação de Medicamentos/métodos
Hormônio do Crescimento Humano/sangue
Fator de Crescimento Insulin-Like I/metabolismo
Somatostatina/análogos & derivados
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Método Simples-Cego
Somatostatina/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
12629-01-5 (Human Growth Hormone); 51110-01-1 (Somatostatin); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0546



página 1 de 1202 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde